Navigation Links
Cooperation in diabetes research
Date:10/18/2010

The recently signed cooperation agreement between the MPI of Biochemistry and GSK pursues the objective of developing innovative new drugs. The joint research and development work is based on the research findings of Axel Ullrich, Director at the MPI of Biochemistry. He and fellow scientist Mathias Bcker successfully described the role of certain protein molecules - known as kinases - in connection with the development of type II diabetes, a disease in which insulin resistance gives rise to a raised blood sugar level. These kinases make up a group of important signal molecules in the body, which can, under certain circumstances, be involved in the development or manifestation of the disease. In the collaborative project with GSK, the scientists are looking for new substances that can inhibit this kinase activity and control it in a targeted manner.

Axel Ullrich already achieved a milestone in the treatment of diabetes back in 1977, together with fellow scientists at the University of California. At that time, he developed a method of transferring a copy of the human insulin gene into bacteria. This facilitated the industrial manufacture of human insulin for the very first time and has since made it easier for millions of diabetics to live with the disease, as they no longer have to depend on animal insulin, which is not nearly so well tolerated by the human body.

Axel Ullrich's current research is set to contribute to the successful treatment of diabetes a second time. "Developing innovative drugs to treat diabetes gives us the opportunity to directly influence defects in the molecular signal paths, which lie at the root of diabetes. That enables us to fight the actual causes of diabetes," says Ullrich. Peter Gruss, President of the Max Planck Society expressed his delight with the collaboration agreement: "GlaxoSmithKline is one of the world's five major pharmaceutical companies. The collaboration agreement with GSK testifies to the fact that Max Planck Institutes, due to their leading edge in basic research, are also sought-after partners in industry. Max Planck researchers generate ideas for new approaches in application-oriented industrial research. We hope that together with a strong partner, we will be able to translate research findings into therapies which will enhance patient quality of life."

Prof Ullrich's longstanding expertise in molecular biology research is again being put to good use, having already resulted in some very successful therapeutic agents. For example, Herceptin, a drug he developed, is successfully used to treat metastasised breast cancer. The drug Sutent, which treats malignant tumours in the gastrointestinal tract (GIST) and renal cancer (MRCC) is also based on Ullrich's research work. In the case of both of the above drugs, the suppression of certain kinase activity with suitable inhibitors is central to the treatment.


'/>"/>

Contact: Markus Berninger
0049-892-909-1930
Max-Planck-Gesellschaft
Source:Eurekalert

Related biology news :

1. John P. Holdren addresses climate change, stressing need for international cooperation
2. ARS, industry cooperation yields device to detect insects in stored wheat
3. Leading entomologist to give talk at UCR on communication and cooperation in ant societies
4. HFSP President Arima and Secretary General Winnacker awarded for fostering cooperation with China
5. Nanyang Technological University and UK partners heightens cooperation in water industry
6. World-class innovation through international cooperation
7. T cell discovery shows promise for Type 1 diabetes treatment: UBC-CFRI study
8. Garlic oil shows protective effect against heart disease in diabetes
9. National study finds strong link between diabetes and air pollution
10. Biologists discover biochemical link between biological clock and diabetes
11. Women with diabetes having more C-sections and fetal complications: study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/15/2016)... , March 15, 2016 ... report published by Transparency Market Research "Digital Door Lock Systems ... Forecast 2015 - 2023," the global digital door lock systems ... Mn in 2014 and is forecast to grow at a ... of micro, small and medium enterprises (MSMEs) across the world ...
(Date:3/11/2016)... Germany , March 11, 2016 http://www.apimages.com ... - Cross reference: Picture is available at AP Images ( http://www.apimages.com ... from DERMALOG will be used to produce the new refugee identity ... other biometric innovations, at CeBIT in Hanover ... scanner from DERMALOG will be used to produce the new refugee ...
(Date:3/9/2016)... NEW YORK , March 9, 2016 ... current and future states of the RNA Sequencing (RNA ... in segments such as instruments, tools and reagents, data ... Analyze various segments of the RNA-Sequencing market such ... RNA-Sequencing services Identify the main factors affecting each segment ...
Breaking Biology News(10 mins):
(Date:5/27/2016)... May 27, 2016 At present, the ... in this space know that volatility is what makes this ... on ActiveWallSt.com: Synta Pharmaceuticals Corp. (NASDAQ: SNTA ), ... (NASDAQ: LPTN ), and Heat Biologics Inc. (NASDAQ: ... to the technical alerts for these stocks at: ...
(Date:5/26/2016)... and READING, England , ... ( http://www.indegene.com ), a leading global provider of ... pharmaceutical and healthcare organisations and TranScrip ( http://www.transcrip-partners.com ... support throughout the product lifecycle, today announced the ... of IntraScience.      (Logo: http://photos.prnewswire.com/prnh/20141208/720248 ...
(Date:5/26/2016)... May 26, 2016 Despite the volatility ... in this space. Today,s pre-market research on ActiveWallSt.com directs the ... Inc. (NASDAQ: RDUS ), Cerus Corp. (NASDAQ: ... ), and Five Prime Therapeutics Inc. (NASDAQ: FPRX ... at: http://www.activewallst.com/ On Wednesday, ...
(Date:5/26/2016)... CA (PRWEB) , ... May 26, 2016 , ... ... and manufacturing company, today announced several positive developments that position the Company for ... a result of the transaction, Craig F. Kinghorn has been appointed Chairman of ...
Breaking Biology Technology: